- Supported exchanges /
- F /
- 61N1.F
STAGEZERO LIFE SCIENC. (61N1 F) stock market data APIs
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada.
STAGEZERO LIFE SCIENC. Financial Data Overview
| 0.0175 | |
| 0.0175 | |
| - | |
| 0.0175 | |
| 0.0175 | |
| 0.0155-0.0315 | |
| 3 358 K | |
| 124 M | |
| 2 994 K | |
| 0.074 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
STAGEZERO LIFE SCIENC. Fundamental Data is available in our Financial Data APIs
- Net Revenue 2 994 K
- EBITDA -4 463 996
- Earnings Per Share -0.11
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get STAGEZERO LIFE SCIENC. Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get STAGEZERO LIFE SCIENC. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
